THE HUMAN IMMUNE SYSTEM
TRANSFUSION
|
Question
[CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]
|
|
|
Chronic myelomonocytic leukemia
|
|
|
BCR-ABL negative chronic myeloid leukemia
|
|
|
BCR-ABL positive chronic myeloid leukemia
|
|
|
Myelo/lymphoproliferative syndrome with PDGFRA rearrangement
|
|
|
Myelo/lymphoproliferative syndrome with PDGUK rearrangement
|
Detailed explanation-1: -Myeloid/lymphoid neoplasms with PDGFRB rearrangement is a distinct type of neoplasm occurring in association with rearrangement of PDGFRB at 5q32 and associated with t(5; 12)(q31-33; p12). Most patients have splenomegaly and some have hepatomegaly.
Detailed explanation-2: -WHO classification of acute lymphoblastic leukemia. The WHO classifies ALL as B-lymphoblastic leukemia/lymphoma or T-lymphoblastic leukemia/lymphoma.
Detailed explanation-3: -AML is arranged into two families: AML with defining genetic abnormalities. AML, NOS is no longer applicable. Most AML with defining genetic abnormalities may be diagnosed with <20% blasts. AML-MR replaces the former term AML “with myelodysplasia-related changes”, and its diagnostic criteria are updated.
Detailed explanation-4: -The most important difference between the WHO and FAB classifications is the lowering of the blast threshold for the diagnosis of AML from 30% to 20% blasts in the blood or bone marrow. As a result, the FAB category RAEBT is eliminated from the WHO proposal (Table 2).